Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2025-03-20
Target enrollment:
Participant gender:
Summary
Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized
by the progressive loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc)
and aggregation of Lewy bodies in neurons. Although aging, oxidative damage and
neuroinflammation have been recognized to play crucial roles in the pathogenesis of PD, the
precise etiology remains obscure. Emerging evidence suggests PD is a systemic metabolic
disease, and metabolic abnormality correlates with functional alternations in PD
Phase:
Phase 2
Details
Lead Sponsor:
Tanta University
Collaborators:
Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa Metformin